2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial
暂无分享，去创建一个
M. Dowsett | R. Gelber | J. Baselga | B. Leyland-Jones | A. Goldhirsch | M. Untch | D. Cameron | M. Piccart-Gebhart | C. Köhne | C. Jackisch | M. Procter | I. Smith | L. Gianni | R. Bell | M. Andersson | T. Suter | E. McFadden | E. de Azambuja | A. Brunt | D. Heinzmann | E. Azambuja | L. D. Lago | A. Vindevoghel | A. Brunt | H. Weber | San‐tai Song | Evandro de Azambuja | Douglas Otero-Reyes | Richard D Gelber | Martine J Piccart-Gebhart | Thomas M Suter | Harald A Weber | Lissandra Dal Lago | A Murray Brunt | Thomas M. Suter